For research use only. Not for therapeutic Use.
AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1[1]. AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants[2].
| Catalog Number | I044647 |
| CAS Number | 2479276-17-8 |
| Synonyms | 1-(4-aminobutyl)-2-butylimidazo[4,5-c]quinolin-4-amine;trihydrochloride |
| Molecular Formula | C18H28Cl3N5 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H25N5.3ClH/c1-2-3-10-15-22-16-17(23(15)12-7-6-11-19)13-8-4-5-9-14(13)21-18(16)20;;;/h4-5,8-9H,2-3,6-7,10-12,19H2,1H3,(H2,20,21);3*1H |
| InChIKey | ZSUHKPUPLPQJGC-UHFFFAOYSA-N |
| SMILES | CCCCC1=NC2=C(N1CCCCN)C3=CC=CC=C3N=C2N.Cl.Cl.Cl |
| Reference | [1]. Sung-Ju Moon, et al. Compositions containing, methods and uses of antibody-tlr agonist conjugates. Patent WO2020168017A1. [2]. Shelley Erin ACKERMAN, et al. Immunoconjugates targeting pd-l1. Patent WO2020190734A1. |
